This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Silvano Dragonieri
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. Galectin-3 is β-galactoside-binding lectin with several roles in immune-inflammatory response. To date, there is no evidence of Galectin-3 role as a prognostic predictor in COVID-19 disease. The aim of this study is to clarify the prognostic role of Galectin-3 in patients with COVID 19 acute respiratory failure.
Methods. We enrolled 156 consecutive patients with COVID-19 disease. Routine laboratory test, arterial blood gas, chest X-ray or Computed Tomography and Galectin-3 dosage were performed. The primary outcome was to assess Galectin-3 predictive power for 30-day mortality. Secondary outcomes were 30-day Intensive Care Unit admission and Acute Respiratory Distress Syndrome stratification according to Galectin-3 dosage. We performed Mann-Whitney U and Kruskal-Wallis tests for continuous variables comparison. Fisher’s exact test or Chi-square test were used for categorical variables analysis. Relationships between Galectin-3, clinical and laboratory data were identified using Spearman analysis. Receiver Operating Characteristic curves estimated Galectin-3 predictive power for the endpoints. With a fixed cut-off of 35.3 ng/ml, Kaplan-Meier with Log-Rank test and Cox Regression were performed to assess mortality and Intensive Care Unit admission risk.
Results. Galectin-3 correlated with many other prognostic predictors tested in our analysis. Moreover, patients with serum levels of Galectin-3 above 35.3 ng/ml had increased risk for mortality, Intensive Care Unit admission and severe Acute Respiratory Distress Syndrome.
Conclusions. Our study demonstrates the role of Galectin-3 as a predictor of mortality, Intensive Care Unit access and ARDS stratification in patients with COVID 19 acute respiratory failure.
Keywords
ARDS, ICU, inflammation, lung injury
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
- AdditionalFile1.docx
• File name: Additional file 1 • File format: .doc • Title of data: Demographic and clinical characteristics of patients. • Description of data: descriptive table of clinical and demographic features of our cohort
- AdditionalFile2.docx
• File name: Additional file 2 • File format: .doc • Title of data: Correlations between Galectin-3, clinical and laboratory data • Description of data: table comparing Galectin 3 with clinical and laboratory features
- AdditionalFile3.docx
• File name: Additional file 3 • File format: .doc • Title of data: Receiving operator characteristic curve for laboratory, clinical and arterial blood gas data • Description of data: table of ROC analysis
- AdditionalFile4.docx
• File name: Additional file 4 • File format: .doc • Title of data: Comparison of clinical and laboratory data according to ARDS severity • Description of data: table comparing clinical and laboratory data for ARDS degree
- AdditionalFile5.docx
• File name: Additional file 5 • File format: .doc • Title of data: Receiving operator characteristic analysis for mild ARDS Galectin-3 cut-off • Description of data: ROC curve for mild ARDS and Galectin 3 cut off
- AdditionalFile6.docx
• File name: Additional file 6 • File format: .doc • Title of data: Receiving operator characteristic analysis for moderate ARDS Galectin-3 cut-off • Description of data: ROC curve for moderate ARDS and Galectin 3 cut off
- AdditionalFile7.docx
• File name: Additional file 7 • File format: .doc • Title of data: Receiving operator characteristic analysis for severe ARDS Galectin-3 cut-off • Description of data: ROC curve for severe ARDS and Galectin 3 cut off
- AdditionalFile8.docx
• File name: Additional file 8 • File format: .doc • Title of data: Receiving operator characteristic curve for ARDS severity • Description of data: table of ROC analysis for ARDS degree and Galectin 3 cut off
- AdditionalFile9.docx
• File name: Additional file 9 • File format: .doc • Title of data: Mild and moderate ARDS Kaplan-Meier curves according to Galectin-3 cut-off. • Description of data: Kaplan-Meier curves stratifing mild and moderate ARDS for Galectin 3 cut off
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 24 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Critical Care & Emergency Medicine
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Silvano Dragonieri
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 24 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Critical Care & Emergency Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. Galectin-3 is β-galactoside-binding lectin with several roles in immune-inflammatory response. To date, there is no evidence of Galectin-3 role as a prognostic predictor in COVID-19 disease. The aim of this study is to clarify the prognostic role of Galectin-3 in patients with COVID 19 acute respiratory failure.
Methods. We enrolled 156 consecutive patients with COVID-19 disease. Routine laboratory test, arterial blood gas, chest X-ray or Computed Tomography and Galectin-3 dosage were performed. The primary outcome was to assess Galectin-3 predictive power for 30-day mortality. Secondary outcomes were 30-day Intensive Care Unit admission and Acute Respiratory Distress Syndrome stratification according to Galectin-3 dosage. We performed Mann-Whitney U and Kruskal-Wallis tests for continuous variables comparison. Fisher’s exact test or Chi-square test were used for categorical variables analysis. Relationships between Galectin-3, clinical and laboratory data were identified using Spearman analysis. Receiver Operating Characteristic curves estimated Galectin-3 predictive power for the endpoints. With a fixed cut-off of 35.3 ng/ml, Kaplan-Meier with Log-Rank test and Cox Regression were performed to assess mortality and Intensive Care Unit admission risk.
Results. Galectin-3 correlated with many other prognostic predictors tested in our analysis. Moreover, patients with serum levels of Galectin-3 above 35.3 ng/ml had increased risk for mortality, Intensive Care Unit admission and severe Acute Respiratory Distress Syndrome.
Conclusions. Our study demonstrates the role of Galectin-3 as a predictor of mortality, Intensive Care Unit access and ARDS stratification in patients with COVID 19 acute respiratory failure.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
- AdditionalFile1.docx
• File name: Additional file 1 • File format: .doc • Title of data: Demographic and clinical characteristics of patients. • Description of data: descriptive table of clinical and demographic features of our cohort
- AdditionalFile2.docx
• File name: Additional file 2 • File format: .doc • Title of data: Correlations between Galectin-3, clinical and laboratory data • Description of data: table comparing Galectin 3 with clinical and laboratory features
- AdditionalFile3.docx
• File name: Additional file 3 • File format: .doc • Title of data: Receiving operator characteristic curve for laboratory, clinical and arterial blood gas data • Description of data: table of ROC analysis
- AdditionalFile4.docx
• File name: Additional file 4 • File format: .doc • Title of data: Comparison of clinical and laboratory data according to ARDS severity • Description of data: table comparing clinical and laboratory data for ARDS degree
- AdditionalFile5.docx
• File name: Additional file 5 • File format: .doc • Title of data: Receiving operator characteristic analysis for mild ARDS Galectin-3 cut-off • Description of data: ROC curve for mild ARDS and Galectin 3 cut off
- AdditionalFile6.docx
• File name: Additional file 6 • File format: .doc • Title of data: Receiving operator characteristic analysis for moderate ARDS Galectin-3 cut-off • Description of data: ROC curve for moderate ARDS and Galectin 3 cut off
- AdditionalFile7.docx
• File name: Additional file 7 • File format: .doc • Title of data: Receiving operator characteristic analysis for severe ARDS Galectin-3 cut-off • Description of data: ROC curve for severe ARDS and Galectin 3 cut off
- AdditionalFile8.docx
• File name: Additional file 8 • File format: .doc • Title of data: Receiving operator characteristic curve for ARDS severity • Description of data: table of ROC analysis for ARDS degree and Galectin 3 cut off
- AdditionalFile9.docx
• File name: Additional file 9 • File format: .doc • Title of data: Mild and moderate ARDS Kaplan-Meier curves according to Galectin-3 cut-off. • Description of data: Kaplan-Meier curves stratifing mild and moderate ARDS for Galectin 3 cut off
Loading...